-
Clinical and Experimental Gastroenterology
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Stem cell therapeutics: potential in the treatment of inflammatory bowel disease
Review
(2489) Views (1115) Full article downloads
Authors: ES Swenson, ND Theise
Published Date January 2010
Volume 2010:3 Pages 1 - 10
DOI: http://dx.doi.org/10.2147/CEG.S6836
ES Swenson1, ND Theise2
1Department of Internal Medicine, Section of Digestive Diseases, Yale University School of Medicine, New Haven, CT, USA; 2Departments of Pathology and Medicine (Division of Digestive Diseases), Beth Israel Medical Center – Albert Einstein College of Medicine, New York, NY, USA
Abstract: Stem cell therapies may be valuable in treatment of inflammatory bowel disease (IBD). Here we focus on two very different types of stem cells – hematopoietic stem cells and mesenchymal stem cells. Myeloablation and hematopoietic stem cell transplantation alter host immune response by reconstituting the recipient’s blood cell lines with donor cells. Autologous hematopoietic reconstitution may “reboot” mucosal immunity to a normal baseline state, but does not alter any underlying genetic predisposition to IBD. In contrast, allogeneic hematopoietic transplantation reconstitutes all blood lineages from a tissue-matched donor who presumably does not have a genetic predisposition to IBD. Compared with autologous hematopoietic transplantation, allogeneic hematopoietic transplantation carries a much greater risk of complications, including graft-versus-host disease. Mesenchymal stem cells can give rise to cartilage, bone and fat in vitro, but do not reconstitute hematopoiesis after transplantation. Systemically infused mesenchymal stem cells appear to favorably downregulate host immune responses through poorly understood mechanisms. In addition, mesenchymal stem cells may be applied topically to help close fistulas associated with Crohn’s disease. For all of these stem cell therapy applications for IBD, only cases and small series have been reported. Larger clinical trials are planned or ongoing.
Keywords: inflammatory bowel disease, Crohn’s disease, stem cell therapy, bone marrow transplant, mesenchymal stem cell
- Testimonials
"You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio
- Oropharyngeal Crohn’s disease
- Amino acid-responsive Crohn's disease: a case study
- Methylnaltrexone in the treatment of opioid-induced constipation
- Selected luminal mucosal complications of adult celiac disease




